Navigation Links
Nastech Announces Third Quarter 2007 Financial Results
Date:10/29/2007

d to $16.2 million, or $0.77 per share, for the prior year period. The increase in the net loss from the prior year periods is due to a combination of lower revenue and higher spending due to increased clinical activities, headcount growth, and expenses related to research and development projects. The net loss for the prior year nine month period includes a cumulative benefit from the accounting change of adopting SFAS123(R) in January 2006 of approximately $0.3 million reflecting the net cumulative impact of estimating future forfeitures in the determination of period expense for restricted stock awards, rather than recording forfeitures when they occur as permitted prior to 2006.

Research and development expenses for the current quarter increased $3.3 million to approximately $13.8 million as compared to the prior year period and increased $8.4 million to $39.4 million for the nine months ended September 30, 2007 from the prior year period. This year-to-date net increase reflects an actual increase of approximately $12.5 million in R&D expenditures, primarily due to increases in clinical activities, the number of research and development employees and related infrastructure costs. The prior year nine month period included a $4.1 million charge due to in-process R&D expenses related to our acquisition of RNAi intellectual property from Galenea Corp. in the first quarter 2006.

Selling, general and administrative expenses increased $1.6 million to approximately $5.1 million for the current quarter compared to the prior year quarter and increased $4.0 million to approximately $14.5 million for the nine months ended September 30, 2007 from the prior year period, primarily due to increases in patent and legal costs necessary to support our business model as well as our growth.

We ended the third quarter of 2007 with approximately $58.1 million in cash, cash equivalents and investments compared to $51.0 million at December 31, 2006, including $2.2 mill
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Dr. Robert Hanzlik, whose ... toxicity carries implications for advancing the creation of safer ... National University , the second-largest private, nonprofit university ... Hanzlik, a professor at the University of Kansas School ... design, starts at 5 p.m. and takes place at ...
(Date:4/27/2015)... April 27, 2015 ... please scroll to bottom . Investor-Edge ... Pharmaceuticals Inc. (NASDAQ: LXRX ), Idera Pharmaceuticals ... (NASDAQ: SNTA ), Spectrum Pharmaceuticals Inc. (NASDAQ: ... MDVN ). Free research report on Lexicon Pharma ...
(Date:4/27/2015)... and HEIDELBERG , Germany ... Addresses unmet need in treatment of millions of ... has been granted a patent in Europe ... patent supports Molecular Health,s discovery that EPHB4 is a novel ... promotes tumor growth. EPO stimulates the production of red blood ...
(Date:4/27/2015)... 2015 Diasome Pharmaceuticals, Inc. (“Diasome”) ... Joslin Diabetes Center (“Joslin”) to collaborate on the ... novel Hepatocyte Directed Vesicle (“HDV”) targeting system for ... , Located in Boston, Massachusetts, Joslin is the ... organization dedicated to the prevention, treatment and cure ...
Breaking Biology Technology:Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2
... Imago Scientific Instruments has sold one of ... of Engineering for use in the new W.M. ... lab will be the primary research center of ISU's ... Narasimhan, an associate professor of chemical and biological engineering. ...
... has secured $5 million in a funding round led ... LLC. , ,The funding will allow Jellyfish to ramp up ... conjunction with the funding, retail industry veteran Ralph Dillon, managing ... of Directors. , ,Jellyfish has gained traction in online retailing ...
... research team at the Medical College of Wisconsin ... National Heart, Lung, and Blood Institute to support ... which was awarded to an investigative team led by pediatric ... molecular and clinical understanding of Von Willebrand disease ...
Cached Biology Technology:Online retailer Jellyfish.com lands $5M in funding 2Online retailer Jellyfish.com lands $5M in funding 3Medical College secures $9.7M research grant 2
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... the American Society of Tropical Medicine and Hygiene (ASTMH) -- ... bring together in one place global experts who are battling ... that each year kill or sicken hundreds of millions of ... medicine and global health will present new insights and research ...
... N.C. -- Recognizing that some of the leading ... are located in the Research Triangle Park area, ... $13.6 million grant to establish a multi-university center ... scientific endeavor. Researchers from Duke University, North ...
... Bethesda, MDA new commentary published online in The FASEB ... diligent and demand proof of safety and benefit before ... treatments have very little scientific evidence that they actually ... the article, Phillip J. Baker, Ph.D., Executive Director of ...
Cached Biology News:Latest on malaria, dengue, radiation threats, bedbugs, cholera in Haiti at ASTMH Annual Meeting 2Latest on malaria, dengue, radiation threats, bedbugs, cholera in Haiti at ASTMH Annual Meeting 3NSF establishes Triangle (NC) Center for Soft Matter Research 2NSF establishes Triangle (NC) Center for Soft Matter Research 3Chronic pain: Watch out before accepting diagnosis and treatment 2